Medidata Solutions

Medidata Solutions

Medidata was founded in 1999 and is headquartered in New York, with additional offices in San Francisco, Tokyo, and London. The company began as a clinical data management platform and has since expanded into a full-lifecycle operating system for clinical research. Its platform integrates patient recruitment, randomization, trial supply management, data collection, and regulatory submission. Medidata's strategy centers on a unified platform that spans three core experiences: patient engagement, data management, and study delivery. It covers asset classes including clinical operations software, RTSM (randomization and trial supply management), regulatory solutions, and AI-powered analytics. The firm's platform serves pharmaceutical sponsors, contract research organizations (CROs), and clinical sites across therapeutic areas such as oncology, rare disease, and central nervous system disorders. Confirmed customers include ICON, Worldwide Clinical Trials, and Everest Clinical Research (per the firm, 2025). Geographic footprint covers North America, Europe, and Asia Pacific. The platform is used in thousands of clinical trials globally. Medidata reports that its technology was used in 90% of FDA novel drug approvals in 2025. The company processes over 4 billion data points annually and is used by more than 1 million patients (per the firm, 2025). In 2025, Medidata's second annual AI report found that 72.9% of early adopters saw a reduction in study timelines, indicating a shift from pilots to enterprise AI adoption (per the firm, 2025). The firm also offers a synthetic control arm solution, which received FDA acceptance for a Phase III glioblastoma trial design. Medidata's structural differentiator is its role as the dominant data infrastructure for clinical trials rather than a pure software vendor. Its platform is embedded into the workflows of regulators (FDA), sponsors, and CROs, creating high switching costs and network effects. The AI imaging solution launched in 2025 and the synthetic control arm capability represent efforts to move beyond data management toward predictive trial design.